Pular para o conteúdo
Merck
Todas as fotos(1)

Documentos Principais

SML2482

Sigma-Aldrich

Ticagrelor

≥98% (HPLC)

Sinônimo(s):

Ticagrelor, (1S,2S,3R,5S)-3-[7-{[(1R,2S)-2-(3,4-difluorophenyl)cyclopropyl]amino}-5­(propylthio)-3H-[1,2,3]-triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol, (1S,2S,3R,5S)-3-[7-{[(1R,2S)-2-(3,4-Difluorophenyl)cyclopropyl]amino}-5-(propylsulfanyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)-1,2-cyclopentanediol

Faça loginpara ver os preços organizacionais e de contrato

Selecione um tamanho

10 MG
R$ 415,00
50 MG
R$ 837,00

R$ 415,00


Check Cart for Availability

Solicite uma grande encomenda

Selecione um tamanho

Alterar visualização
10 MG
R$ 415,00
50 MG
R$ 837,00

About This Item

Fórmula empírica (Notação de Hill):
C23H28F2N6O4S
Número CAS:
Peso molecular:
522.57
Número MDL:
Código UNSPSC:
12352200
NACRES:
NA.77

R$ 415,00


Check Cart for Availability

Solicite uma grande encomenda

Ensaio

≥98% (HPLC)

Formulário

powder

atividade óptica

[α]/D -55 to -65°, c = 0.2 in methanol

cor

white to beige

solubilidade

DMSO: 2 mg/mL, clear

temperatura de armazenamento

−20°C

cadeia de caracteres SMILES

FC1=C(F)C=C([C@]2([H])C[C@@]2([H])NC3=NC(SCCC)=NC4=C3N=NN4[C@]5([H])C[C@H](OCCO)[C@@H](O)[C@H]5O)C=C1

InChI

1S/C23H28F2N6O4S/c1-2-7-36-23-27-21(26-15-9-12(15)11-3-4-13(24)14(25)8-11)18-22(28-23)31(30-29-18)16-10-17(35-6-5-32)20(34)19(16)33/h3-4,8,12,15-17,19-20,32-34H,2,5-7,9-10H2,1H3,(H,26,27,28)/t12-,15+,16+,17-,19-,20+/m0/s1

chave InChI

OEKWJQXRCDYSHL-FNOIDJSQSA-N

Informações sobre genes

human ... P2RY12(64805)

Procurando produtos similares? Visita Guia de comparação de produtos

Descrição geral

Ticagrelor (AZD6140) is a cyclopentyl-triazolopyrimidine.[1]

Ações bioquímicas/fisiológicas

Ticagrelor is an antithrombotic antiplatelet drug that acts by direct and reversible competitive inhibition of the adensoine purinoceptor P2Y12 receptor. It has clinical benefits in people affected with acute coronary syndrome. It might also play a beneficial role on endothelial function. Ticagrelor can prevent the uptake of adenosine by human erythrocytes and can promote the liberation of adenosine triphosphate (ATP) from human erythrocytes.[1]

Código de classe de armazenamento

11 - Combustible Solids

Classe de risco de água (WGK)

WGK 3

Ponto de fulgor (°F)

Not applicable

Ponto de fulgor (°C)

Not applicable


Escolha uma das versões mais recentes:

Certificados de análise (COA)

Lot/Batch Number

Não está vendo a versão correta?

Se precisar de uma versão específica, você pode procurar um certificado específico pelo número do lote ou da remessa.

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Os clientes também visualizaram

Slide 1 of 5

1 of 5

Athanasios Moulias et al.
Journal of cardiovascular pharmacology and therapeutics, 24(1), 11-17 (2018-07-12)
Ticagrelor is a P2Y12 receptor antagonist with proven clinical benefit in patients with acute coronary syndrome. Apart from its principal antiplatelet action, pleiotropic effects have been implicated in the clinical profile of ticagrelor, including a potentially beneficial impact on endothelial
Michał J Kubisa et al.
Therapeutics and clinical risk management, 14, 129-140 (2018-02-06)
Novel antiplatelet drugs, including ticagrelor, are being successively introduced into the therapy of atherothrombotic conditions due to their superiority over a standard combination of clopidogrel with acetylsalicylic acid in patients with acute coronary syndromes (ACS). A P2Y12 receptor antagonist, ticagrelor
José C Nicolau et al.
Expert opinion on pharmacotherapy, 19(9), 1013-1019 (2018-06-13)
Cardiovascular disease (CVD) is the main cause of death in the world. Coronary artery disease (CAD) is the most common form of CVD presentation, but the prevalence of peripheral artery disease (PAD) is increasing. Patients with polyvascular disease comprise a
Riyaad Aungraheeta et al.
Blood, 128(23), 2717-2728 (2016-10-04)
Ticagrelor is a potent antagonist of the P2Y12 receptor (P2Y12R) and consequently an inhibitor of platelet activity effective in the treatment of atherothrombosis. Here, we sought to further characterize its molecular mechanism of action. Initial studies showed that ticagrelor promoted

Questions

Reviews

No rating value

Active Filters

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica